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Canine MDCK cell lines are refractory to infection with human
and mouse prions
Abstract
Influenza vaccine production in embryonated eggs is associated with many disadvantages, and
production in cell culture systems is a viable alternative. Madin Darby canine kidney (MDCK) cells are
permissive for a variety of orthomyxoviruses and have proven particularly suitable for vaccine mass
production. However, mammalian cells harboring the Prnp gene can theoretically acquire prion
infections. Here, we have attempted to infect MDCK cells and substrains thereof with prions. We found
that MDCK cells did not produce any protease-resistant PrP(Sc) upon exposure to brain homogenates
derived from humans suffering from Creutzfeldt-Jakob disease (CJD) or from mice infected with Rocky
Mountain Laboratory (RML) scrapie prions. Further, transmission of MDCK lysates to N2aPK1 cells
did not induce formation of PrP(Sc) in the latter. PrP(C) biogenesis and processing in MDCK cells were
similar to those of prion-sensitive N2aPK1 cells. However, steady-state levels of PrP(C) were very low,
and PrP(C) did not partition with detergent-resistant membranes upon density gradient analysis. These
factors may account for their resistance to infection. Alternatively, prion resistance may be related to the
specific sequence of canine Prnp, as suggested by the lack of documented prion diseases in dogs.
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Influenza vaccine production in embryonated eggs is associated with many 
disadvantages, and production in cell culture systems is a viable alternative. Madin 
Darby Canine Kidney (MDCK) cells are permissive for a variety of orthomyxoviruses and 
have proven particularly suitable for vaccine mass production. However, mammalian 
cells harboring the Prnp gene can theoretically acquire prion infections. Here we have 
attempted to infect MDCK cells and substrains thereof with prions. We found that MDCK 
cells did not produce any protease-resistant PrPSc upon exposure to brain homogenates 
derived from humans suffering from Creutzfeldt-Jakob disease (CJD) or from mice 
infected with Rocky Mountain Laboratory (RML) scrapie prions. Further, transmission of 
MDCK lysates to N2aPK1 cells did not induce formation of PrPSc in the latter. PrPC 
biogenesis and processing in MDCK cells were similar to those of prion-sensitive 
N2aPK1 cells. However, steady-state levels of PrPC were very low, and PrPC did not 
partition with detergent-resistant membranes upon density gradient analysis. These 
factors may account for their resistance to infection. Alternatively, prion resistance may 
be related to the specific sequence of canine Prnp, as suggested by the lack of 
documented prion diseases in dogs.  
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Abstract 
Influenza vaccine production in embryonated eggs is associated with many 
disadvantages, and production in cell culture systems is a viable alternative. Madin 
Darby Canine Kidney (MDCK) cells are permissive for a variety of orthomyxoviruses and 
have proven particularly suitable for vaccine mass production. However, mammalian 
cells harboring the Prnp gene can theoretically acquire prion infections. Here we have 
attempted to infect MDCK cells and substrains thereof with prions. We found that MDCK 
cells did not produce any protease-resistant PrPSc upon exposure to brain homogenates 
derived from humans suffering from Creutzfeldt-Jakob disease (CJD) or from mice 
infected with Rocky Mountain Laboratory (RML) scrapie prions. Further, transmission of 
MDCK lysates to N2aPK1 cells did not induce formation of PrPSc in the latter. PrPC
biogenesis and processing in MDCK cells were similar to those of prion-sensitive 
N2aPK1 cells. However, steady-state levels of PrPC were very low, and PrPC did not 
partition with detergent-resistant membranes upon density gradient analysis. These 
factors may account for their resistance to infection. Alternatively, prion resistance may 
be related to the specific sequence of canine Prnp, as suggested by the lack of 
documented prion diseases in dogs. 
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Introduction
Influenza viruses A and B are enveloped RNA viruses, whose genome consists of eight 
segments of linear negative-sense, single-stranded RNA. They are the causative agents 
of acute respiratory disease and are responsible for over 40,000 deaths [1] and 100,000 
hospitalizations [2] in the US per year. Immunization remains the most efficient strategy 
of prevention against influenza and currently more than 250 million doses of inactivated 
influenza vaccines are being brought to the market every year [3]. Influenza vaccines 
include representative strains of influenza A (H1N1 and H3N2) and influenza B viruses. 
Due to the high antigenic drift, influenza vaccine composition is adjusted annually based 
on information collected by various National Influenza Centers worldwide and the 
recommendations on the World Health Organization [4]. 
At present, influenza vaccines are derived from virus propagation in embryonated 
chicken eggs, a procedure that is time-consuming and labor-intensive. Moreover, 
immunization with egg-derived vaccines is associated with sensitization against egg 
proteins and it is contraindicated in subjects with a known history of egg-allergy [5]. 
Therefore alternative vaccine production methods, devoid of the drawbacks of the in ovo 
system are required.  
The most attractive method for influenza vaccine production is mammalian cell culture 
systems, such as Madin Darby canine kidney (MDCK) cells [4, 6-8]. The original MDCK 
cell line was established in 1958 by Madin & Darby [9] and a few years later it was 
recognized that MDCK cells are readily permissive for a wide variety of flu strains [10, 
11]. 
A major safety concern associated with influenza and other vaccines and 
biopharmaceuticals produced in mammalian cells refers to the risk of replicating prions, 
which are unconventional infectious agents causing transmissible spongiform 
encephalopathy (TSE) in humans and a wide variety of animals. TSEs are invariably 
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fatal neurodegenerative diseases, such as scrapie in sheep, bovine spongiform 
encephalopathy (BSE) in cattle and Creutzfeldt–Jakob disease (CJD) in humans. Prions 
were shown to replicate in vitro within various cell lines, including the common laboratory 
fibroblast cell lines NIH/3T3 and L929, indicating that any cell line expressing normal 
host prion protein could have the potential to support propagation of TSE agents [12]. 
Therefore testing the prion replication competence of cell lines used for preparation of 
drugs intended for human – or animal – use becomes imperative. 
The goal of the current study was to test whether MDCK cells are capable of replicating 
prions. Several different MDCK cell sublines exist, most of which exhibit an epithelial-like 
phenotype [13]. Starting from such a subline, that is MDCK 666, we have previously 
developed and characterized a suspension-like cell clone, designated MDCK 33016 
(deposit number DSM ACC 2219 WO 97/37001 and US Patent 6656720 “Animal cells 
and processes for the replication of influenza viruses”). The latter was further adapted to 
serum- and protein-free medium conditions, leading to a subline named MDCK 33016-
PF, currently used by Novartis Vaccines and Diagnostics, for development of influenza 
vaccine. Here, we first characterized various sublines of MDCK cells in terms of PrPC
expression, Prnp sequence, and subcellular localization. In addition, we evaluated 
whether endogenous cellular prion protein (PrPC) expression levels are modified during 
influenza virus infection. Finally we investigated the susceptibility of MDCK 33016-PF 
cells to mouse-adapted scrapie and most importantly human CJD prions.
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Materials and Methods
Cell lysates, Immunoprecipitation and Western Blotting
The MDCK 33016-PF cell line was grown adherently in presence of 2% FCS for all 
analyses except for the scrapie cell assays (SCA) and infection with influenza virus, 
where no FCS was added. Cells were washed twice with PBS and then detached by 
scraping. Cells were centrifuged and then lysed in different buffers containing proteinase 
inhibitors (Roche, Complete Mini, protease inhibitor cocktail, prod. no. 11836153001). 
Lysates intended for Western blot or ELISA were prepared in RIPA buffer (50mM Tris 
pH 7,4, 1% NP40, 0.25% deoxycholic acid sodium salt, 150mM NaCl, 1mM EGTA). 
Total protein concentration was estimated using a standard colorimetric method based 
on bicinchoninic acid (Pierce Biotechnology, Rockford, IL, USA). For 
immunoprecipitation experiments, lysates were prepared in PBS with 1% NP40 and 
0.25% deoxycholate. After two rounds of snap freezing and thawing, the cell debris were 
precipitated by centrifugation at 500 g for 3 min and the supernatants were collected. For 
western blots, 100µg of total proteins per well were analyzed on a NuPAGE 12% Bis-
Tris gel (Invitrogen, prod. no. NP0342BOX). The proteins were transferred to a 
nitrocellulose membrane, blocked with 5% Top Block (Fluka), and then probed with 
primary antibodies. POM1 (2mg/mL, 1:10000), POM11 (1mg/mL, 1:5000), biotinylated 
POM1 (1mg/mL, 1:1000) and POM2 (1mg/mL, 1:5000) were used to detect PrPC and a 
monoclonal antibody against actin (Chemicon, Cat no. MAB1501R, 1mg/mL, 1:8000) 
was used for loading control. For secondary antibodies anti-mouse IgG1-HRP (Zymed, 
1mg/mL, 1:18000) and avidin-HRP (BD Biosciences Pharminogen, prod. no. 554058, 
1:7000) were used. Blots were developed by using HRP substrate (enhanced 
chemiluminescent substrate; Pierce), and signals were acquired with Versadoc 3000 
imaging system (Bio-Rad, Hercules, CA, USA). For immunoprecipitation 250µg of total 
protein diluted in 1mL of PBS with 3% Tween-20 and 3% NP40 (PAA) was incubated 
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with 50µL of Dynabeads coupled to POM1 for 90 min at room temperature. The beads 
were collected with a Dynal Magnetic Particle Concentrator (MPC-S, Invitrogen), washed 
four times with 2% PAA and one time with 3% PAA. The beads were spun down, 
collected with the MPC and dissolved in 20µL of 2x sample buffer. Samples were loaded 
on a NuPAGE 12% gel. After blocking with 5% Top Block in PBST, blots were incubated 
with biotinylated POM1 or biotinylated POM11 (diluted in 1% Top Block/PBST) for 1 
hour, washed 3 times for 10 min and then incubated for 1 hour with avidin-HRP (1:7000, 
diluted in 1% Top Block/PBST). 
Flotation assay
We used two different protocols for the flotation assay. In the first protocol, we used 
OptiPrep for the gradient and in the second one we used Nycodenz. In protocol 1, cells 
were grown in 150mL flasks to confluency. They were washed twice with ice cold PBS 
and then scraped in 1mL ice cold MBS buffer (25mM MES (pH 7), 150mM NaCl, 2mM 
EDTA and protease inhibitors) and kept on ice for all following steps. Cells were 
homogenized by passing through a 26G needle, 10-12 times and then centrifuged at 
1000g for 5 minutes. 500µL of the supernatant was collected and mixed with 500µL of 
MBS buffer. It was then sonicated 6 times for 5 sec and after one minute, another six 
times for 5 sec (Sonicator Labsonic 2000 from B.Braun). For the gradient, 1mL sample 
was mixed with 2mL of 60% of ice cold OptiPrepTM (Lot No. 06F01S01, Axis-Shield PoC 
AS, Oslo) and placed in the bottom of an ultracentrifuge tube (50 Ultra-ClearM Tubes 16 
x 102 mm, Lot No. P6 11 09). 6mL of 30% and 3mL of 5% OptiPrepTM (in MBS) were 
then added on the sample. The gradients were centrifuged for 5 hours at 32’000 rpm 
(180,000 g) with a sw32 rotor in a Beckman Ultracentrifuge at 4°C. 12 fractions were 
collected and the proteins were acetone-precipitated. 300µL of the samples were mixed 
1:4 with ice cold (-20°C) acetone and kept at -80°C for 2 hours or over night. After 
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spinning at 16,000 g for 20 min at 4°C, supernatants were discarded and pellets were 
air-dried. Pellets were then resuspended with 80µL loading buffer and boiled for 4 min at 
95°C. The fractions were loaded on a 12%NuPAGE gel. Prion protein was detected with 
POM-1 (1:10,000) and the raft fractions were confirmed by detection of Flotillin with a 
purified mouse anti-flotillin antibody (BD Biosciences Pharmingen, cat. nr: 610821; 
dilution 1:10,000).  
Flotation of detergent-insoluble complexes with Nycodenz was performed as described 
by Naslavsky et al [14]. Confluent cells growing in two 10-cm plates (about 3 × 107 cells) 
were incubated with 400 µL of lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM 
ETDA, 1% Triton X-100) on ice in a cold room for 30 min. All subsequent steps were 
performed at 4 °C. Lysates were adjusted to 35% Nycodenz by adding an equal volume 
of ice-cold 70% Nycodenz prepared in TNE (25 mM Tris, pH 7.5, 150 mM NaCl, 5 mM 
EDTA) and loaded at the bottom of Beckman Instruments TLS-55 ultracentrifuge tubes. 
A 8-35% Nycodenz linear step gradient in TNE was then overlaid above the lysate 
(200 µL each of 25, 22.5, 20, 18, 15, 12, and 8% Nycodenz), and the tubes were spun at 
55,000 rpm for 4 h at 4 °C in a TLS-55 rotor (gav, 200,000 × g). Fractions were collected 
from the top of the tube. 
ELISA
96-well plates (Nunc-Immuno Maxisorb; prod. no. 439454) were coated with 50µL per 
well of POM1 (2mg/mL, 1:5000 in 0.1M sodium carbonate buffer pH 9.6 [1.58g Na2CO3
+ 2.94g NaHCO3 in 500mL H2O]) over night at 4°C. All following incubation steps were 
made at room temperature. The plates were washed by immersing them 4-5 times in 
PBS with 0.1% Tween-20 (PBST). Plates were then incubated with 100µL per well of 
blocking buffer (5% Top Block in PBST) for two hours. A 1:3 dilution of recombinant 
murine PrP (rmPrP) (starting from 50ng/mL) was used for a standard curve. Cell lysates 
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(250µg/mL or 500µg/mL of total protein) and brain homogenates (50µg/mL of total 
protein) were prepared in sample buffer (1% Top Block in PBST) and incubated for 1 
hour. Then, plates were washed 4-5 times in PBST and incubated with biotin-labeled 
POM2 (1mg/mL, 1:5000 in sample buffer, 100µL per well) for 1 hour. Plates were 
washed 4-5 times and incubated with avidin-HRP (1mg/mL, 1:1000 in sample buffer, 
100µL per well) for 1 hour followed by another round of washing, 4-5 times in PBST and 
2-3 times with PBS alone. Chromogenic substrate (Biosource, pro. no. SB02, 50µL per 
well) was applied for up to 10 min. The reaction was stopped with 0.5M H2SO4 and 
absorbance was read at 450nm. 
For POM1 affinity determinations, 96-well plates (Nunc-Immuno Maxisorb; prod. no. 
439454) were coated with 10ng/mL recombinant murine or canine PrP (rmPrP and rcPrP 
respectively). After washing and blocking, a limiting dilution of purified POM1 antibody 
was incubated for 1hour at room temperature. After washing, the plate was incubated 
with an anti-mouse IgG1-HRP secondary antibody (Zymed, 1mg/mL, 1:18000) and the 
reaction was visualized with a chromogenic substrate as described above. Bacterially 
expressed human prion proteins (a kind gift from Dr K Wuthrich, Institute for Molecular 
Biology and Biophysics, Swiss Federal Institute of Technology, Zurich, Switzerland) 
were produced and purified as described previously [15].
Flow cytometric analysis
Cells were detached from flasks with EDTA. 700,000 cells in 100µL FACS buffer (2% 
FCS, 2% EDTA, 0.5M, pH 8 and 1 g NaN3 in PBS) were put in each well of a 96-well 
round bottom uncoated plate. The cells were spun down at 1700 g for 5 min and the 
supernatants were discarded. The cells were resuspended in 100µL of the antibodies 
(POM2-Cy5, POM1 or IgG1-Cy5 and IgG1 for isotype control respectively, 1:1000 in 
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FACS buffer) and incubated for 30 min on ice. The cells were spun down at 1700 g for 5 
min and supernatants were discarded. The POM1 stained cells were incubated with the 
secondary antibody (anti-mouse IgG1-Cy5) for 30 min on ice. The cells were washed 
twice with FACS buffer and transferred into micro-tubes. 
Immunocytochemistry
For immunostaining, 10-10,000 cells were grown in gelatin coated chamber slides for 4 
days. The cells were rinsed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 
min at room temperature followed by 10 min of incubation with NH4Cl (20mM in PBS). 
After 10 min of blocking in 5% goat serum and PBS, the cells were incubated with POM-
1 antibody (1:500 in 5% goat serum) for 1 hour and washed three times for 5 min with 
PBS. They were incubated with the secondary antibody IgG Alexa546 (1:1000) for 1 
hour. After rinsing with PBS, the chambers were covered with Fluorescin. 
Sequencing of genomic DNA for the Prnp gene
Genomic DNA was extracted from cells and dog brain (cerebellum and hippocampus) 
with the Nucleo Spin Tissue Kit (Macherey-Nagel, cat. no. 740952.50). The cells were 
grown in 75mL flasks to confluency and detached with EDTA or Trypsin. They were 
washed with PBS and spun down at 500g. One third of the pellet was incubated with 
200µg/mL proteinase K (PK) for 3.5 hours at 56°C. From the brain, small pieces were 
cut and incubated for 6 hours at 56°C. For the PCR, dog PrP primers were purchased 
from Microsynth and the PCR was run with 1µL of DNA, 1µL of both primers and a 
master mix from Promega (GoTaq Green Master Mix, cat. no. M7113). Cycles: 95°C for 
3 min, 30 times a cycle of 95°C for 20 sec, 60°C for 30 sec and 72°C for 1 min followed 
by 1 time 7 min at 72°C and storage at 4°C. 50µL of the PCR product was run on an 
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agarose gel (1.5%). The bands were cut from the gel and purified with the Qiagen gel 
extraction kit (cat. no. 28104). 100ng was sent to be sequenced.
Influenza infection of MDCK 33016 cells
The seed virus preparations, which were used for the infection of the MDCK 33016 cells, 
are based on the vaccine reference strains provided by the National Institute for 
Biological Standard and Control, Herforthshire, UK. The strains are recommended for 
the vaccine of the Influenza Season 2006/2007 in the Northern Hemisphere. 
 A/New Caledonia/20/99 IVR-116
 A/Wisconsin/67/2005 X-161b  
 B/Malaysia/2506/2004-like 
The virus strains were inoculated in a serial dilution ranging from MOI 10-5 up to 10-7
using 1x106 cells/mL prepared in an infection medium supplemented with trypsin 
(10µg/mL) according to the Novartis vaccine process. The infection experiments were 
carried out in spinner flask in a total volume of 250mL. Sham-treated but not virus 
infected cell cultures were performed for control. Cell pellets and supernatants (50mL 
each) were collected for PrPc quantification at various time points from 6hpi up to 72hpi. 
Infection kinetic of the influenza virus and virus yields were followed by a staining of 
influenza infected cells with an anti-influenza antibody (Imagen prod. No K610511-2; 
DAKO Cytomation; Germany) and by quantification in a standard hemagglutination (HA) 
assay using chicken red blood cells. 
Prion infection and scrapie cell assay (SCA)
N2aPK1 cells (17,000 per well), MDCK 33016 (15,000 per well; grown without FCS) and 
HpL cells (8000 per well) were plated on a micro-titer 96-well plate and were grown for 
16 hours at 37°C. The medium was then replaced by 300µL of mock or RML (Rocky 
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Mountain Laboratory (RML) strain of mouse-adapted scrapie) or CJD brain homogenate, 
diluted in growth medium (10-3 dilution of wet brain tissue). All CJD cases included in this 
study were derived from the tissue bank of the Swiss National Reference Centre of Prion 
Diseases (NRPE) in Zurich. For all tissue specimens originated from patients referred to 
NRPE, consent to examine autopsy material had been obtained from each patient or 
legal guardian. The four different CJD samples we used for infecting MDCK-cells have 
been extensively characterized previously by immunohistochemistry and Western Blot 
analysis and the CJD diagnosis was definite [16, 17]. In addition, two out of the four CJD
samples have been independently inoculated in transgenic mice carrying the human 
PRNP gene and presence of prion infectivity was confirmed in vivo (data not shown). 
The cells were grown to confluency and then (approximately after three days) they were 
split 1:3. The medium was taken off and kept under sterile conditions. The cells were 
detached with 30µL EDTA (2mM) for 20 min at 37°C. The old medium was put back and 
the cells were further detached by pipetting up and down 20-30 times, 100µL were 
transferred to a new plate and filled up with fresh medium. This was repeated twice. 
Cells were further split 1:10 several times with completely fresh medium, in order to 
remove any residual inoculum. The first assay was completed after 3x 1:3 and 3x 1:10 
splits and repeated after several more splits. 
All solutions used for the assay were filtered in advance. The plates (Millipore, 
MultiScreen sterile white plates cat. no. S2EM004M99) were activated by adding 50µL of 
pure ethanol (70%) to each well for 1 min, sucked off - using a vacuum pump and rinsed 
twice with 160µL of PBS. The cells were suspended in 300µL of medium and 80µL
(approximately 25,000 cells) were transferred to each well, vacuum was applied and the 
plates were dried for 90 min at 50°C until all wells had dried. The wells were incubated 
with 50µL of Proteinase K solution (0.5µg/mL for the N2aPK1 and 0.25µg/mL for the 
MDCK and HPL cells in lysis buffer: 50mM TrisHCl pH 8, 150mM NaCl, 0.5% Na 
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deoxycholate, 0.5% Triton X-100 [Sigma] and H2O) for 90 min at 37°C and washed twice 
with 160µL of PBS. 160µL PMSF (100mM in Isopropanol diluted 1:100 in PBS) was 
added for 10 min at room temperature and sucked off followed by a 10 min incubation 
with 160µL of Tris-guanidinium thiocyanate (GSCN, 3M in 10mM TrisHCl pH 8 in H2O) 
and 4 washes with 160µL of PBS on the vacuum pump. For blocking, 160µL of blocking 
buffer (5% Top-Block [Fluka, cat. no. 37766] in TBST (10mM TrisHCl pH 8, 150mM NaCl 
and 0.1% Tween-20) was added and incubated for 1 hour at room temperature and then 
sucked off. Wells were then incubated with 50µL of POM1 or POM12 (2mg/mL diluted 
1:5000 in 1% Top-Block in TBST) for 1 hour at room temperature. The supernatants 
were discarded and the plate was washed once with TBST and discarded again before 
washing 7 times with 160µL of TBST on vacuum pump. Then, 50µL of anti-IgG1-HRP 
(Zymed, prod. no. 61-0120, 1mg/mL was diluted 1:1000 in 0.1% Top-Block and TBST) 
was added for 1 hour, discarded and washed once with TBST and discarded before 
another 7 times of washing on the pump. 100µL of supersignal ELISA Pico 
chemiluminescent substrate (Socochim, prod. no. 37070) was added, incubated for 5 
min at room temperature and relative light units (RLU) were measured by a luminometer. 
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Results
Characterization of PrPC in MDCK cells
Expression of PrPC is a prerequisite for any cell or organism to support prion replication 
[18] thus is a crucial determinant of prion infectability of MDCK cells. We have recently 
developed and characterized a panel of high affinity monoclonal antibodies with epitopes 
that span the entire murine prion protein (mPrPC) [16]. We have used two of these 
antibodies, designated POM1 (epitope within amino acids [aa] 121 to 230) and POM11 
(epitope aa 64 to 72 and 72 to 80) on a standard Western blotting protocol. In Figure 1A 
we compared equal amounts of total protein (100µg) from lysates of MDCK as well as 
cells known to express substantial amounts of mPrPC, such as a murine fibroblast cell 
line, i.e. 3T3-NIH cells. In addition we used cell lysates from murine hippocampal cell 
lines derived from Prnp+/+, designated HW, or from Prnp-/- mice, called HpL [19], for 
positive and negative controls respectively. We found that in all three MDCK cell lysates, 
PrPC was detectable, but in levels significantly lower than that of HW or 3T3-NIH cells 
(Figure 1A). We confirmed the specificity of the signals by concentrating PrPC from cell 
lysates by means of immunoprecipitation (data not shown). 
Next, we quantified PrPC levels in MDCK cells in comparison to all other cell lines 
presented above. To this end, we used a highly specific and sensitive sandwich ELISA 
(Enzyme-linked immunosorbent assay) protocol, that takes advantage of combinations 
of POM antibodies with non-competing epitopes [20], i.e. POM1 for capturing PrPC and 
biotinylated POM2 (epitope aa 58 to 64, 66 to 72, 74 to 80, and 82 to 88) for detection. 
We have used a serial dilution of rmPrP solutions (starting from 50ng/mL) to create 
standard curves for normalization (data not shown). PrPC levels in MDCK cell lines were 
found to be in a range of approximately 10ng per mg of total protein. This corresponds to 
roughly 5 times less than N2aPK1 cell lysates and 10 times less than wild type mouse 
brain homogenate (Figure 1B). Interestingly, the progenitor MDCK cell line (666) was 
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found to express about twice as much PrPC as MDCK 33016 cell line whereas the 
original clone (ATCC) had the lowest PrPC levels. This was about 5ng PrPC per mg of 
total protein, which is slightly above the detection limit of the assay. The low PrPC levels 
in MDCK cells were not due to lower affinity of the antibodies used against canine PrP
(Supplementary Figure 1).  
We next wanted to determine DNA and amino acid sequences of Prnp and PrPC
respectively. We isolated total DNA from all three MDCK cell lines as well as a dog brain 
homogenate and we amplified their Prnp gene by PCR. We then sequenced the 
respective PCR products and compared them to the published sequences for dog Prnp
gene and its translation product. 
Genomic DNA sequence alignments of the published Prnp gene, compared to the 
sequences we acquired from either MDCK cell lines (marked as ‘cells’; all three MDCK 
cells showed identical sequences) or a dog brain homogenate (marked as ‘brain’), are 
depicted in supplementary Figure 2. We observed four mutations, one of which is 
outside the coding region (position 22, supplementary Figure 2). Of the other three 
mutations, the one at position 780 is silent (CCC in published and cells substituted by 
CCT in brain), since in both cases the amino acid proline is encoded. The other two 
mutations at positions 352 (ATG in published and brain substituted by GGT in cells) and 
540 (GAG in published and cells substituted by GAC in brain) encode for an amino acid 
exchange in the respective proteins. In Figure 1C, we compared the amino acid 
sequences of the translation product (cPrPC) of the DNA sequences shown in 
supplementary Figure 2. We found that the three sequences differed only at two 
positions. Serine at position 101 of the published and the dog brain PrPC sequence is 
replaced by a glycine in all three MDCK cell lines. In addition, Glutamic acid at position 
163 is substituted by aspartic acid in the dog brain sequence, but is unchanged in MDCK 
cells. It is difficult to assess whether these amino acid substitutions impinge on the 
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secondary structure of PrPC, but we think that they probably represent natural 
polymorphic sites on dog PrPC.
Subcellular localization of PrPC on MDCK cells 
Cell-surface localization of PrPC has been shown to be necessary for prion infection of 
cells in vitro [21] and for neurotoxicity and prion pathology in vivo [22]. We used flow 
cytometry to verify that PrPC is properly localized on the cell surface of MDCK cells. In 
Figure 2A we compared the different cell lines using POM2, previously shown to bind 
native, cell-bound PrPC in flow cytometry (data not shown). We found that MDCK cells 
are positive, indicating that PrPC is located on their cell surface. Same is true for 3T3-
NIH fibroblasts, HW and N2aPK1 cells, which show approximately one log higher
expression levels of PrPC than MDCK cells, supporting our Western Blot and ELISA data 
(Figure 1A and B). No PrPC was detected in HpL cells, since those cells are derived from 
Prnp-/- mice, validating the specificity of the assay. We used immunocytochemistry of 
fixed, non-permeabilized MDCK cell lines to confirm cell-surface localization of PrPC. 
MDCK cell lines the original clone ATCC, or 33016, murine fibroblast cell line (3T3-NIH) 
and murine hippocampal cell lines derived from Prnp-/- mice (HpL) were stained the anti-
PrP antibody POM1 (Figure 2B). All cells with the exception of the PrPC-deficient HpL 
cells show a positive signal for PrPC that seems to be mainly on the plasma membrane. 
Physiologically PrPC was found to be attached to the plasma membrane by a 
glycosylphosphatidylinositol (GPI)-anchor, in all cells and tissues tested so far. Like most 
GPI-linked proteins, PrPC resides in cholesterol-enriched microdomains of cell 
membranes, often referred to as lipid rafts [14]. Following extraction in cold Triton X-100 
and ultracentrifugation on density gradients, proteins associated with lipid rafts float in 
the uppermost fractions. Since proper subcellular localization of PrPC in lipid rafts is very 
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likely to play a vital role in the prion susceptibility of these cells, we compared MDCK cell 
lines to N2aPK1 cells by density gradient flotation assays. 
We used two independent density gradient flotation protocols to compare raft fractions 
from cell lysates of murine neuroblastoma cell line (N2aPK1) and three different MDCK 
cell lines and found a mislocalization of PrPC in MDCK cells (Figure 3A and B). In 
N2aPK1 cells, fractions with the highest levels of PrPC, as well as Flotillin, are floating on 
the top of the gradient, indicating that PrPC in those cells is properly localized within the 
rafts (Figure 3A and B, most upper panel). In all three MDCK cell lines, however, PrPC is 
exclusively found in the bottom fractions of the gradient, suggesting that there is little or 
no PrPC associated with lipid rafts in those cells (Figure 3A three lower panels and 
Figure 4B, lower panel). Interestingly in all MDCK cell lines, flotillin seems to localize 
properly, showing highest band intensity in the floating fractions and the rest distributing 
within the bottom fractions. This is expected, since during preparation some rafts are 
disrupted and proteins are leaking in the lower part of the gradient. We wondered if this 
mislocalization of cPrPC occurs also within the dog brain tissue; in other words whether 
our findings represent a general defect of cPrPC. We compared density gradient flotation 
fractions from mouse versus dog brain tissue (Figure 3C) and found no significant 
differences. This indicates that failure of cPrPC to associate with raft fractions occurs only 
within MDCK-cells, presumably due to the very low PrPC in these cells.
Monitoring of PrPC expression levels in MDCK cells during influenza infection 
Expression of PrPC as well as several other proteins can be affected by manipulations 
that have an impact on cell cycle, metabolism and generally cell homeostasis. It is 
known that induction of stress in any cell may result in up- or down-regulation of genes. 
It is conceivable that influenza virus infection of MDCK-cells may lead to an uncontrolled 
up-regulation of Prnp, as well as other genes, in response to the stress induced by the 
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virus to the cell. This may result in a significant increase in the levels of PrPC, which 
might render MDCK cell lines susceptible to prions, due to adequate availability of the 
substrate for prion conversion. If that were the case, replicated prions might also end up 
in the supernatant of disrupted cells. 
We addressed the above questions, by analyzing PrPC levels in MDCK-cell lysates and 
supernatants at various time points after infection with a range of influenza virus strains 
and doses. We have used the three influenza virus strains that are included in the 
influenza vaccine for the 2006/2007 Influenza Season in the Northern Hemisphere. 
These are A/New Caledonia/20/99 (H1N1)-like virus, A/Wisconsin/67/2005 (H3N2)-like 
virus and B/Malaysia/2506/2004-like virus. We infected one million MDCK 33016 cells 
with three different virus doses: one high, one intermediate and one low virus dose. We 
first checked for the virus infection efficiency after 24hrs and after 48hrs. As expected, a 
small percentage of the cells (20-40%) were infected by the virus 24 hours post infection 
(hpi), but more than 90% of the cells were infected at 48hpi (data not shown). Cells and 
cell supernatants were harvested at 6, 24, 48 and 72 hpi and were analyzed by 
sandwich ELISA for PrPC. In Figure 4 PrPC levels in cell lysates (upper panel) and cell 
supernatants (lower panel) of virus infected or uninfected cells are compared. We 
observed some variation between the different timepoints, potentially reflecting 
regulation of PrPC during the cell cycle. However, we did not observe any up-regulation 
of PrPC in the influenza infected cells at any timepoint and with any virus strain. On the 
contrary infection of MDCK-cells with influenza virus B/Malaysia resulted in a reduction 
of PrPC in the cell-lysates over time. 
Our results indicate that influenza virus infection does not cause any increase in PrPC
levels neither in the cells, nor in their supernatant. On the contrary, it seems that virus 
infection may lead to a decrease in the amounts of PrPC, which is likely a consequence 
of the harmful effects of the virus on the cells, leading to increased proteolytic activity.
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Determination of conversion efficiency of canine PrPC in MDCK cells
SCA using mouse adapted scrapie prions
We then asked whether this cPrPC in MDCK cells can be converted into PrPSc, after 
inoculation with infectious prion isolates. We have addressed this question by exposure 
of MDCK cells to different prion agents including RML (Rocky Mountain Laboratories, a
mouse-adapted sheep scrapie strain) and most importantly to different types of sporadic 
CJD (Creutzfeldt-Jakob Disease). Conversion efficiency was determined by detection of 
proteinase K resistant PrP (PrPres) using SCA and by western blot. 
At first, cells were exposed to a prion-containing brain homogenate, diluted in growth 
medium for 3 days. After several splits, in which the original inoculum is sufficiently 
diluted, cells are transferred on an ELISPOT plate, where they were subjected to limited 
proteolysis which digests PrPC. The presence of the pathologic isoform, the scrapie prion 
protein (PrPSc), which is proteinase resistant, is then detected using a specific anti-PrP 
antibody on a chemiluminescence-based assay.
We have used RML prions which are readily replicated in vitro by the neuroblastoma cell 
line, N2aPK1, which serves as a positive control for our experiments. Moreover, the 
hippocampal cell line HpL, which was derived from Prnp-/- cells, is a negative control, 
since those cells lack PrPC, which is the required substrate for prion replication and are 
thus resistant to prions. We repeatedly found that the only cell line giving a positive 
signal in this assay is N2aPK1 cells, whereas both MDCK-cells and the PrPC-deficient 
HpL cells seem to be resistant to RML-prions (Figure 5A and B; representative of six 
independent experiments). 
Next, we expanded N2aPK1 and MDCK 33016 cells that have been exposed to RML 
prions and we prepared lysates, which we used to assess the presence of PrPSc by an 
independent method. We performed proteinase K (PK) digestion and analyzed the 
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lysates by Western Blots and found that in accordance with the SCA results, MDCK cells 
did not contain any PK-resistant PrP (data not shown). Moreover, we concentrated PrPSc
from the cell lysates, using phosphotungstate (NaPTA) precipitation, thereby increasing 
the sensitivity of detection (Figure 5C). Again, we failed to detect any PK-resistant 
material in the MDCK cell lysates (Figure 5C, upper panel) whereas N2aPK1 cells were 
positive (Figure 5C, lower panel). 
We then went on to exclude the possibility that a phenomenon called the ‘species 
barrier’, which is observed in vivo accounted for the apparent resistance of MDCK-cells 
to mouse adapted scrapie prions. Species barrier refers to the fact that prions isolated 
from one species are often less infectious to other species, as evident by longer 
incubation times and reduced attack rates in experimental animals. This is thought to 
depend on dissimilar host prion protein sequences, thereby hindering the conversion 
process. Upon serial passages, incubation times gradually decrease, a phenomenon 
called “adaptation”. In some cases the species barrier is so strong that certain hosts do 
not show any clinical disease upon inoculation of prions from other species. 
Nevertheless, brain isolates of these apparently resistant hosts can transmit disease 
when inoculated to susceptible hosts [23, 24]. For this reason, we wanted to assess 
whether lysates from MDCK-cells (carrying canine PrPC) exposed to RML prions 
(originated from murine PrPC) may contain infectivity that would only be apparent in a 
second passage of infection on MDCK-cells. In other words, we wanted to check 
whether a phenomenon like adaptation may occur in the cells. 
We exposed MDCK 33016, N2aPK1 and HpL cells to cell-lysates prepared from RML-
inoculated MDCK or N2aPK1 cells. We did not detect any infectivity in the MDCK cell 
lysates, regardless of whether they were used to infect N2aPK1 or MDCK cells. 
Moreover, MDCK cells were resistant to infection by RML-infected N2aPK1-cell lysates 
(Figure 5D). The latter, however evidently carried prion infectivity, since they could infect 
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N2aPK1 cells (Figure 5D). The detection limit of infectivity derived from cell-lysates was 
determined to be 10-5 cell lysate (Supplementary Figure 3).
SCA using Creutzfeldt-Jakob disease samples
Next we tested whether MDCK 33016 cells could be infected with CJD prions. We have 
chosen a variety of brain tissue samples from the tissue bank of the National Reference 
Center for Prion Diseases (NRPE). The samples we used for infecting MDCK-cells have 
been extensively characterized previously by immunohistochemistry and Western Blot 
analysis and the CJD diagnosis was definite [16, 17]. In addition, two of the four samples 
have been independently inoculated in transgenic mice carrying the human PRNP gene 
and presence of prion infectivity was confirmed in vivo (data not shown). 
All samples used for inoculations were derived from sporadic CJD cases (sCJD). In 
sCJD, biochemically distinguishable types of sCJD have been identified and were 
proposed to represent distinct prion strains. Biochemical properties of PrPSc are currently 
used as a surrogate ‘strain’-typing marker for CJD, allowing molecular classification 
CJD. In addition to the possible effects of protein conformation, the host genotype at 
polymorphic site of the human prion protein, codon 129 (Met or Val) influences the 
course of disease and CJD type. We have recently generated monoclonal antibodies 
which differentiate types 1 and 2 of CJD and found that all CJD type 2 and vCJD cases 
that were analyzed have small amounts of type 1 in at least one brain area [16]. 
For all following experiments, we selected sCJD samples of different types (type 1, or 2 
or type 1+2), all of which were homozygous for Methionine at position 129, in order to 
match the endogenous PrPC sequence of MDCK and N2aPK1 cells. Both cell types are 
expected to be homozygous for Methionine at the respective site, since Valine at 
position 129 is unique for human PrPC sequence; all other animal PrPs analyzed to date 
are homozygous for Methionine at the respective site (see Figure 1C Methionine at 
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position 134; numbering of cPrPC is 5 amino acids shifted when compared to human). 
sCJD samples chosen for MDCK cell infections, were controlled for carrying prion 
infectivity in vivo by transmission to transgenic mice overexpressing the human prion 
protein (data not shown).
We first analyzed the sCJD samples in SCA by limiting dilution in order to define the 
sensitivity of SCA in the case of CJD (data not shown). We found that a 10-3 dilution of 
wet brain tissue is ideal for detection by SCA, whereas 10-5 was in most cases the 
detection limit of this assay. For infecting the cells, 10-3 dilution was used, since this is 
the highest dose that does not harm the cells and was therefore used for all further 
experiments.
SCA results of the CJD inoculation experiments showed that neither MDCK 33016, nor 
N2aPK1 cells are able to replicate human prions (Figure 6A). As a positive control for 
the assay a CJD brain homogenate was mixed with fresh MDCK cells and put on the 
ELISPOT plate (marked as ‘221-1 hom.’). In addition RML-infected cells were used for 
positive control. To confirm that the CJD inoculated cells were devoid of PK-resistant 
PrPSc, we used phosphotungstate (NaPTA) precipitation with or without proteinase K 
(PK). Again we found that lysates from MDCK-cells were devoid of PrPSc (Figure 6B, left 
blot). Under the same conditions, PrPSc is readily detectable in RML-inoculated N2aPK1 
cell lysates. As a positive control, diluted samples of the same CJD brain homogenates 
were used (Figure 6B, right blot). 
We went on to check whether a phenomenon like adaptation may occur in the CJD-
inoculated cells, following a similar protocol as for the RML-infected cells. We exposed 
MDCK 33016 cells to cell lysates prepared from sCJD-infected either MDCK or N2aPK1 
cells. We did not detect any infectivity in the MDCK cells after incubation of sCJD-
inoculated MDCK 33016 cell-lysates (Figure 6C). Moreover, MDCK cells were resistant 
to infection by sCJD-inoculated N2aPK1-cell lysates (Figure 6C). Furthermore, in 
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accordance with the SCA results, MDCK cell lysates did not contain any detectable PK-
resistant PrP, after NaPTA precipitation (Figure 6D).
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Discussion
Immunization remains the most efficient strategy of prevention against influenza. At 
present, influenza vaccines are prepared in embryonated chicken eggs, a procedure that 
has many disadvantages. Firstly, it is time-consuming, labor-intensive, and 
uneconomical since it requires 1-2 eggs per dose of vaccine produced [3]. Moreover, 
cultivation of influenza viruses in eggs was shown to select for mixed subpopulations 
which can be antigenically distinct from each other and from the original strain, 
potentially compromising egg-derived vaccine efficacy [25]. Finally, immunization with 
egg-derived vaccines can elicit sensitization to egg proteins, such as ovalbumin. Their 
presence in vaccines may be linked to adverse effects and subjects with a known history 
of egg allergy are currently excluded from influenza vaccination programs. Since 
influenza vaccines are intended for annual re-immunization, the repeated administration 
may lead to immune reactions against egg proteins, leading to a reduced tolerability 
profile of the product [5]. For all the above reasons, influenza vaccine production in 
chicken eggs is far from optimal. 
In the recent years, a highly pathogenic avian influenza virus A of the subtype H5N1, 
has affected humans. This virus has the potential to become the next pandemic strain 
either unchanged or after reassortment with human influenza viruses A [26]. Luckily, 
avian influenza virus seems to spread poorly among humans and has not caused a 
pandemic yet, although since 2003 it has claimed the lives of 165 people worldwide [27]. 
However, due to continuous mutagenesis (antigenic drift) and genetic reassortment 
(antigenic shift) of the virus, concerns for a new influenza pandemic have not ceased. In 
case of a new influenza pandemic, alternative methods of vaccine production, superior 
in terms of speed, reliability consistency and flexibility of the manufacturing process as 
well as the efficiency and safety of the final product will become essential.
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The most attractive alternative method for influenza vaccine production relies on
mammalian cell cultures. Several cell lines such as Madin Darby canine kidney (MDCK) 
cells [4, 6, 7], African green monkey kidney Vero cells [28], human retina-derived cell 
line Per.C6 [29] and St. Jude porcine lung cells (SJPL) [30] have been tested for the 
production of influenza vaccines. While all those cell lines have major advantages 
towards the conventional egg-based vaccine production method, MDCK cell line is 
arguably the best-characterized cell culture system for influenza virus replication [9]. 
MDCK cells are readily permissive for a wide variety of flu strains [10, 11] and lately 
optimal conditions for growing an influenza vaccine in MDCK cell line cultivated in a 
serum-free medium were determined [7]. Comparison of egg- to MDCK-grown influenza 
vaccine showed that the latter induced superior protection of ferrets against subsequent 
challenge with infectious virus grown in either host cell type [6].
A major safety concern associated with influenza and other vaccines and 
biopharmaceuticals produced in mammalian cells refers to the risk of replicating prions 
the infectious agents of transmissible spongiform encephalopathy (TSE), invariably fatal 
neurodegenerative diseases such as scrapie of sheep, bovine spongiform 
encephalopathy (BSE) of cattle, and Creutzfeldt–Jakob disease (CJD) of humans. BSE 
has been transmitted to humans through the consumption of contaminated beef, 
resulting in the emergence of a new human prion disease, named variant CJD (vCJD), 
affecting predominantly young adults [31]. Following the occurrence of BSE in three 
continents since 1986 [32-34] the need to ensure the TSE safety of vaccines has 
become vital. One approach is to avoid, whenever possible, tissues from animals, risk 
tissues and tissues of unknown or uncertain provenance [35]. While this is a reasonable 
strategy, it is not always feasible to exclude the possibility that any of the material used 
for vaccine production e.g. cell-culture media and additives, viruses or even the cell lines 
themselves, during their, often, long history of passages, have been in contact with prion 
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agents. If the influenza vaccine-producing cells were able to replicate prions, then 
contamination during vaccine preparation would be possible. This would have 
devastating consequences, given that influenza vaccine is distributed to more than 250 
million healthy individuals per year. 
Prion replication in neuronal cell lines was first demonstrated in 1970 [36] and since then 
several studies have established that prion inoculation of certain neuronal cell lines 
results in propagation of infectivity and accumulation of the pathological isoform of the 
prion protein, PrPSc [37, 38]. One of the most commonly used cell line for in vitro prion 
studies is the mouse neuroblastoma cell line N2a which is readily susceptible to mouse 
adapted sheep scrapie prion strains. In fact, these cells can become chronically infected 
with the prion agent and have served as an in vitro model for testing potential 
therapeutic approaches against prion diseases [21, 39]. Several recent reports 
demonstrated that non-neuronal cells can also support TSE infection. Formation of PrPSc
and scrapie infectivity after exposure to sheep scrapie agent was detected in rabbit 
epithelial cells, genetically engineered to express significant levels of sheep prion protein 
[40]. Moreover, the common laboratory fibroblast cell lines 3T3-NIH and L929 were 
found to be susceptible to infection with mouse-adapted scrapie [12]. Most recently, 
scrapie infection of murine C2C12 myoblasts and myotubes in vitro following co-culture 
with scrapie-infected N2a cells was demonstrated, albeit infection did not occur after 
incubation with a scrapie-infected non-neuronal cell line or a scrapie brain homogenate 
[41]. The above findings indicate that any cell type that expresses the cellular prion 
protein (PrPC) may be capable of supporting prion-replication. 
MDCK cells originated from a dog kidney. They were found to express detectable but 
low levels of canine PrPC (cPrPC). These were estimated in the range of 2-5ng of PrPC
per mg of total protein which is approximately 1 log lower than those found in other cell 
lines tested, such 3T3-NIH or N2aPK1 cells which are known to possess prion 
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replication competence. Sequence analysis of the Prnp reading frame from MDCK cells, 
which encodes PrPC, revealed two coding discrepancies from Prnp isolated from a dog 
brain homogenate. One of those variations was identical with the published sequence for 
cPrPC, suggesting that it is a natural polymorphic site. The other is unique for MDCK 
cells, and carries an amino acid (glycine at position 101) that is found on PrPC in other 
species (i.e. pig, elk and bovine) and might either reflect a natural polymorphic site or a 
mutation that arose within the cell line. Biosynthesis of PrPC in MDCK cells seems to be 
largely correct, since the protein is glycosylated and located on the surface of the cells. 
However, PrPC in MDCK cells is not found on raft fractions as in all other cases 
described for far. Nonetheless, cPrPC extracted from dog brain homogenate showed the 
anticipated association with raft fractions, suggesting that the observed mislocalization of 
cPrPC is specific for MDCK-cells. This finding is at odds with previously published results 
reporting raft association of PrPC in MDCK cells transfected with mouse PrPC [42]. We 
hypothesize that the observed defect in the subcellular localization in combination with 
the extremely low levels of cPrPC account for their apparent resistance to prions.
The question of whether cPrPC can, by any means, convert into a pathologic isoform 
remains open to date. While there have been several reports of cases of feline 
spongiform encephalopathy during the BSE crisis in the United Kingdom [43] and in 
other countries, there are no reports of TSE-infected dogs. In addition, feline species, 
such as cheetahs and pumas are highly susceptible to TSE infection [44]. It is 
reasonable to assume that canine species have also been exposed to BSE-
contaminated feed, yet they seem to be immune to infection. 
This apparent resistance of canine species to prion infection could result from unique 
structural features in cPrPC. In a recent study both the primary sequences as well as the 
three dimensional structures of cPrPC to feline PrPC (fPrPC) were compared. Four amino 
acid substitutions between the globular domains of cPrPC and fPrPC were found, all of 
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which involve charged residues. A unique charge distribution pattern in cPrPC due to the 
presence of Asp-159 and Arg-177 was hypothesized to correlate with protection of dogs 
against challenge with BSE [15]. 
We investigated whether MDCK can be infected by a mouse adapted sheep scrapie 
strain called Rocky Mountain Laboratory strain (RML). RML readily infects N2aPK1 cells, 
a subline of mouse neuroblastoma N2a cell line. Infection was tested by SCA, as 
previously described [45]. For RML infection of N2aPK1 cells, SCA has a detection limit 
of at least 10-7 dilution of a wet brain tissue. Using this method we found no signs of 
infectivity or accumulation of PrPSc in MDCK 33016 cells after inoculation with the 
maximum possible RML prion dose, which is 10-3 of wet brain tissue. Transmission of 
MDCK 33016 cell-lysates on fresh MDCK cells or N2aPK1 cells was also negative. This 
was important because the prion conversion process is thought to be hindered by 
dissimilarities between host (in our case canine) and inoculum (murine) prion protein 
sequences. Therefore we excluded that lysates from MDCK-cells (carrying cPrPC) 
exposed to RML prions (derived from mPrPC) may contain infectivity that would only be 
apparent in a second passage of infection on MDCK-cells. We also attempted to infect 
MDCK cells with highest possible doses of sporadic CJD brain homogenates (10-3 of wet 
brain tissue) and again found no PrPSc replication by two independent methods (SCA 
and NaPTA precipitation). Transmission of CJD-inoculated MDCK 33016 or N2aPK1 
cell-lysates on fresh MDCK cells again failed to induce any signs of prion infection.
All data described here strongly suggest that MDCK cells do not support prion 
replication. Therefore a transfer of TSE agents by MDCK cells, or lysates thereof, 
appears very unlikely. As always in experimental biology, ‘absence of evidence is not 
evidence of absence’: even if all attempts to infect MDCK cells have failed, their non-
infectability may not be applicable to other theoretically thinkable infection paradigms 
which may have not been tested here. Also, we cannot formally exclude the possibility 
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that MDCK cells replicate very low amounts of prion infectivity, which may go undetected 
with the methods used in this study. Nonetheless, under the conditions tested here, 
MDCK 33016 cells do not support prion replication and do not transfer TSE agents to 
other cell lines that are prion-replication competent.
Acknowledgements: We thank Audrey Marcel for technical assistance on the scrapie 
cell assay experiments.
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Figure Legends
Figure 1: MDCK-cell lines express low, but detectable amounts of PrPC
(A) Western blots from cell lysates from murine hippocampal cell lines derived from 
Prnp+/+ (HW), or from Prnp-/- mice (HpL); murine fibroblast cell line (3T3-NIH), MDCK cell 
lines, original clone (ATCC), progenitor cell line (666), or MDCK 33016 cell line (33016). 
10µg of brain homogenate (BH) and 10ng of rmPrP were used as additional positive 
controls. The two replica blots were incubated with anti-PrP antibodies POM1 (epitope 
within amino acids [aa] 121 to 231; left blot) or POM11 (epitope aa 64 to 72 and 72 to 
80; right blot). Both membranes were also blotted with an anti--actin antibody, as a 
loading control. (B) Sandwich ELISA (Enzyme-linked immunosorbent assay) using two 
anti-PrP antibodies with non-competing epitopes POM1 (capturing antibody) and 
biotinylated POM2 (detecting antibody) was performed. Standard curves using a serial 
dilution of rmPrP solutions (starting from 50ng/mL; data not shown). Cell lysates with a 
total protein concentration of 1mg/mL were used in all cases. Brain homogenates were 
used in a total protein concentration of 50µg/mL. Samples were analyzed in 
quadruplicates. Murine hippocampal cell lines derived from Prnp+/+ (HW), or from Prnp-/-
mice (HpL); murine fibroblast cell line (3T3-NIH), MDCK cell lines, original clone (ATCC), 
progenitor cell line (666), or MDCK 33016 cell line (33016). (C) Amino acid sequence 
alignment of dog PrPC translation product of DNA sequences resulting from MDCK cell 
lines or dog brain homogenate, compared to the protein sequence found in the literature. 
All three MDCK cell lines: MDCK 33016 cell line (33016), original clone (ATCC) and 
progenitor cell line (666) had identical cDNA sequences. Two amino acid substitutions at 
positions 101 and 163, most likely represent natural polymorphic sites on dog PrPC.
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Figure 2: PrPC is located on the cell surface of MDCK cells
(A) Flow cytometric analysis of MDCK cell lines progenitor cell line (666), or MDCK 
33016 cell line (33016), murine fibroblast cell line (3T3-NIH), murine hippocampal cell 
lines derived from Prnp+/+ (HW), or from Prnp-/- mice (HpL) and murine neuroblastoma 
cell line (N2aPK1), using Cy5-labelled anti-PrP antibody (POM2). Forward and side 
scatter blots indicate differences in size and granularity of the cells respectively (left 
column). Propidium Iodide- (PI) staining was used to label dead cells (data not shown). 
Histograms of live cells stained with Cy5-labelled POM2 (red lines) or isotype control are 
shown in the right column. MDCK cells are positive, indicating that PrPC is present on 
the cell surface of those cells. Same is true for 3T3-NIH fibroblast, HW and N2aPK1 
cells, which show approximately one log higher expression levels of PrPC than MDCK 
cells. No PrPC was detected in HpL cells as expected. (B) Immunocytochemistry of fixed, 
non-permeabilized MDCK cell lines the original clone (ATCC), or MDCK 33016 cell line 
(33016), murine fibroblast cell line (3T3-NIH) and murine hippocampal cell lines derived 
from Prnp-/- mice (HpL), using the anti-PrP antibody POM1 (red stain). All cells with the 
exception of HpL show a positive signal for PrPC that seems to be mainly on the plasma 
membrane. In the left panels, negative controls for the stainings are shown, by omitting 
the primary antibody. Cell nucleus was stained with Dapi (blue stain).
Figure 3: PrPC from MDCK cells is not located in lipid rafts
(A) Density gradient flotation assays from cell lysates of murine neuroblastoma cell line 
(N2aPK1) and three different MDCK cell lines: MDCK 33016 cell line (33016), original 
clone (ATCC) and progenitor cell line (666). Fractions of the density gradient were 
immunoblotted with anti-PrP antibody POM1 and with an anti-flotillin antibody, to label 
the rafts. In N2aPK1 cells, fractions with the highest levels of PrPC (2 and 3) are floating 
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on the top of the gradient, indicating that PrPC in those cells is properly localized within 
the rafts. In contrast, in all three MDCK cell lines PrPC is exclusively found in the bottom 
fractions of the gradient, suggesting a mislocalization from the detergent insoluble 
membrane microdomains. (B) This finding was reproducible using an independent 
density gradient flotation protocol for cell lysates of murine neuroblastoma cell line 
(N2aPK1) and MDCK 33016. (C) Density gradient flotation assays from mouse (upper 
panel) or dog (lower panel) showed that cPrPC is properly localized within lipid rafts in 
dog brain cells. This indicates that mislocalization of PrPC in MDCK cells is not a general 
phenomenon of cPrPC, but is specific to MDCK cell lines. For all blots POM1 antibody 
was used.
Figure 4: Influenza virus infection does not lead to an upregulation of PrPC
PrPC levels were checked by sandwich ELISA in all timepoints and virus doses used. We 
did not observe any increase in endogenous levels of PrPC in any case (upper panel). 
Supernatants of influenza infected cells contained little or no detectable PrPC at all times 
(lower panel). 
Figure 5: MDCK 33016 cells are resistant to mouse-adapted sheep scrapie prions
(A) and (B) scrapie cell assay (SCA) of RML-prion inoculation of MDCK 33016, N2aPK1 
and HpL cells. The only samples showing positive signals for PrPSc are N2aPK1 cells. 
Results are representative of six independent inoculation experiments. 
Chemiluminescence image of ELISPOT plate is shown in panel A and the respective 
Relative Light Unit measurements in panel B. (C) Western Blots of Phosphotungstate 
(NaPTA) precipitation with or without proteinase K (PK) digestion as noted (detection 
with POM1 antibody). Although PrPSc is readily detectable in RML-inoculated N2aPK1 
cells, no PrPSc is found in the lysates from MDCK-cells. (D) SCA using N2aPK1 or 
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MDCK 33016 cells inoculated with cell lysates of RML or Mock inoculated MDCK 33016 
or N2aPK1 cells. Although RML-inoculated N2aPK1 cell lysates were able to infect fresh 
N2aPK1 cells, MDCK-cells neither contain any infectivity, nor can they replicate prions 
originating from PK1 or MDCK-cell lysates.
Figure 6: MDCK 33016 cells do not replicate CJD prions, nor do they accumulate 
PrPSc
(A) SCA from cell lysates from CJD-inoculated cells, showing that neither MDCK 33016, 
nor N2aPK1 cells replicate human prions. For positive control here a sCJD brain 
homogenate was mixed with MDCK 33016 cells and used on the ELISPOT plate (black 
bars, 221-1 hom). In addition RML-infected cells were used for positive control. HpL cells 
are a negative control, since these cells do not express endogenous PrPC and therefore 
they cannot replicate prions. (B) Phosphotungstate (NaPTA) precipitation with (500µg of 
proteins) or without (50µg of proteins) proteinase K (PK) digestion as noted. Although 
PrPSc is readily detectable in RML-inoculated N2aPK1 cell lysates, no PrPSc is found in 
the lysates from MDCK-cells (left blot). As a positive control diluted samples of the same 
CJD brain homogenates were used (right blot). Both blots were incubated with POM1 
and anti-mouse IgG. (C) SCA from MDCK 33016 cells inoculated with lysates of sCJD-
incubated N2aPK1 or MDCK 33016 cells as noted. MDCK 33016 cells neither contain 
any infectivity, nor can they replicate prions originating from N2aPK1 or MDCK-cell 
lysates. As positive controls for the assay, we used RML-infected N2aPK1 cells (black 
bar), or a mixture of sCJD brain homogenate (BH) with MDCK 33016 cells processed on 
the ELISPOT plate in parallel with the real samples (grey striped bars, 221 
homogenate). (D) Phosphotungstate (NaPTA) precipitation with or without proteinase K 
(PK) digestion as noted. As positive control here we have used a diluted suspension of 
the original inoculum (sCJD brain homogenate, case 93), Although PrPSc is readily 
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detectable in the diluted inoculum, no PrPSc is found in MDCK 33016 cells inoculated 
with lysates of sCJD-incubated N2aPK1 or MDCK 33016 cells, as noted. Blot was 
incubated with POM1 and anti-mouse IgG.
Supplementary Figure 1: Comparison of POM1 affinity towards murine versus 
canine PrP.
A limiting dilution of POM1 antibody was used on a direct ELISA format on wells coated
with recombinant murine or canine PrP (rmPrP and rcPrP respectively). KD for both 
proteins is approximately 0.5nM, as also confirmed by Biacore measurements (data not 
shown). 
Supplementary Figure 2: Genomic DNA sequence of dog Prnp gene derived from 
MDCK cell-lines shows four mutations when compared to dog brain Prnp
Genomic DNA sequence alignment of dog Prnp gene derived from MDCK cell-lines or 
dog brain homogenate was compared to the published sequence. Mutations at positions 
22 and 780 have no effect on the translation product, since the first one is located 
outside of the coding region, whereas the second one is a silent mutation. Mutations at 
positions 352 and 540 encode for an amino acid substitution, which is shown in Figure 
1C. All three MDCK cell lines had identical DNA sequences.
Supplementary Figure 3: Limit of detection of RML-infected cell lysate.
A limiting dilution of PK1-cell lysate previously infected with RML or MOCK brain 
homogenate was used to infect fresh PK1 cells. After several splits, SCA was performed 
and the limit of detection was determined to be 10-5 cell lysate.
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